Cell/Gene Tx channel feed

Ot­su­ka pens AAV deal with Shape Ther­a­peu­tics for eye gene ther­a­pies

Last year
Deals

Ex­clu­sive: Dana­her’s ven­ture arm backs cell ther­a­py man­u­fac­tur­ing start­up co-found­ed by Carl June

Last year
Startups
Manufacturing

iP­SC biotech Shore­line Bio­sciences wins patent in­fringe­ment suit over Fate, White­head In­sti­tute

Last year
Pharma
Law

Bio­Car­dia un­veils in­ter­im da­ta that led it to stop PhI­II en­roll­ment of heart fail­ure stem cell ther­a­py

Last year
R&D

Beam dos­es first pa­tient with base-edit­ed cell ther­a­py

Last year
R&D

For­mer Al­lo­gene CFO Er­ic Schmidt talks about his new role at Can­tor and the fu­ture of cell ther­a­pies

Last year
People

Sana lays off staff as cell ther­a­py biotech awaits first clin­i­cal da­ta

Last year
People

Cell ther­a­py start­up Notch Ther­a­peu­tics clos­es one of three sites

Last year
People
Startups

Bay­er's cell ther­a­py unit Blue­Rock Ther­a­peu­tics lays off about 50 em­ploy­ees

Last year
People

Leg­end im­proves ac­cess to Carvyk­ti, but cell ther­a­py lags de­mand as biotech seeks ear­li­er-line ap­proval

Last year
Pharma

FDA lifts par­tial hold on Ar­cel­lx’s Gilead-part­nered blood can­cer cell ther­a­py as biotech aims for 2026 launch

Last year
R&D

Taysha rais­es $150M PIPE, shares sin­gle pa­tient da­ta on Rett syn­drome gene ther­a­py

Last year
Financing
R&D

Re­gen­eron to buy gene ther­a­py biotech Deci­bel Ther­a­peu­tics in small $109M deal

Last year
Deals

Po­sei­da lines up an­oth­er al­lo­gene­ic CAR-T part­ner, al­ly­ing with Astel­las on sol­id tu­mors

Last year
Financing

Sarep­ta dos­es first pa­tient with Duchenne gene ther­a­py fol­low­ing ac­cel­er­at­ed ap­proval

Last year
R&D

Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Last year
Financing

Third in line: Ed­i­tas says it may part­ner up on com­mer­cial­iza­tion of sick­le cell gene ther­a­py

Last year
Pharma

In­ter­galac­tic Ther­a­peu­tics, a non-vi­ral gene ther­a­py biotech, lays off all em­ploy­ees

Last year
People
Startups

Ho­mol­o­gy shut­ters de­vel­op­ment as ge­net­ic med­i­cines biotech flash­es ‘for sale’ sign, lays off 80 em­ploy­ees

Last year
People
R&D

Af­ter years of de­lay, Roche takes one of Spark’s he­mo­phil­ia gene ther­a­pies in­to PhI­II, drops an­oth­er

Last year
R&D

Finnish man­u­fac­tur­er to in­vest $55M+ in new fa­cil­i­ty for AAV ther­a­pies

Last year
Pharma
Manufacturing

Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

Last year
Financing
Startups

Ex­clu­sive: Cell ther­a­py CD­MO Kin­cell launch­es, and the spin­out is val­ued at $66M, with CEO look­ing for carve-outs

Last year
Manufacturing

Pas­sage Bio lays off 26% of staff, lets two ex­ec­u­tives go a year af­ter down­siz­ing, lead­er­ship shuf­fle

Last year
People
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times